DisclosureWe earn commission on partner links; ranking is set by clinician-vetted methodology — not advertisers.
Tirzepatide (Mounjaro). Adults with type 2 diabetes inadequately controlled on metformin.
Change in HbA1c at week 40.
A1C reduction 2.01-2.30% with tirzepatide vs 1.86% with semaglutide. Tirzepatide superior at all doses in head-to-head.
Adults with type 2 diabetes inadequately controlled on metformin.
Tirzepatide 5, 10, or 15 mg vs semaglutide 1 mg weekly.
Change in HbA1c at week 40.
A1C reduction 2.01-2.30% with tirzepatide vs 1.86% with semaglutide. Tirzepatide superior at all doses in head-to-head.
Frías JP et al, NEJM 2021;385:503-515